Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO)

Bilen, Mehmet Asım; Martini, Dylan J.; Shabto, Julie M.; Liu, Y.; Khan, Alamzeb; Williams, Milton; Collins, Hannah; Carthon, Bradley Curtis; Akce, Mehmet; Shaib, Walid Labib; Alese, Olatunji B.; Lawson, David H.; Kudchadkar, Ragini R.; El‐Rayes, Bassel F.; Ramalingam, Suresh S.; Owonikoko, Taofeek K.; Harvey, R. Donald; Master, Viraj A.

doi:10.1093/annonc/mdy269.131

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Some clinical parameters can also introduce a misinterpretation of ICIs outcomes. For instance, high performance status or sarcopenia represent two predictive and prognostic factors of poor survivals in particular for patients treated with ICIs even in younger population (49,50). These clinical parameters are more frequent in the elderly population (51).…”

Section: Discussionmentioning

confidence: 99%

Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review

Naltet¹,

Besse²

2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

This article is a review of the literature concerning efficacy and safety of immune checkpoint inhibitors (ICIs) in the elderly population. In the past decade, immunotherapy deeply changed the treatment paradigm of lung cancer in particular in advanced non-small cell lung cancer (aNSCLC). Thus, ICIs have successively demonstrated a survival benefit as single agent in second line, and moved in first line as monotherapy for patients with high programmed death protein 1 (PD-L1) expression or in combination with chemotherapy regardless PD-L1 expression. If patients aged 70 years or older represent up to half of our patients in clinical routine, elderly population is significantly under-represented in clinical trials.This leads to a lack of knowledge concerning efficacy and safety of ICIs in a population of patients with frequent comorbidities, organs dysfunctions and a potential immune-senescence due to age. In this review, we described available data evaluating efficacy and safety of ICI either as monotherapy or in combination in elderly population treated for a lung cancer. These data derived from clinical trial evaluating ICIs in aNSCLC as single agent or in combination with chemotherapy or anti-cytotoxic T-lymphocyte antigen 4 (CTLA-4). As monotherapy, older patients seem to derive the same benefit from ICIs than younger patients with no excess of toxicities. In combination with chemotherapy, real impact of ICIs in elderly population is still unclear. Results of dedicated studies evaluating ICIs as single agent or in combination in elderly patients are needed.

show abstract

Section: Discussionmentioning

confidence: 99%

Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review

Naltet¹,

Besse²

2021

Transl Lung Cancer Res

View full text Add to dashboard Cite

show abstract

“…had lower survival [1.6 months; 95% confidence interval (CI) 1.2-1.8 months] compared with those with elevated NLR without sarcopenia (2.8 months; 95% CI 1.6-4.1 months) or those with low NLR (4 months; 95% CI 2.5-5.4 months) [22].…”

Section: Key Pointsmentioning

confidence: 99%

From cachexia to obesity: the role of host metabolism in cancer immunotherapy

Brocco

Grassandonia

2019

Current Opinion in Supportive &Amp; Palliative Care

View full text Add to dashboard Cite

Purpose of reviewCurrently, several clinical trials in cancer therapy have demonstrated the success of immunomodulatory therapies. However, only a variable fraction of patients actually benefit from these treatments. The understanding of key mechanisms behind this response heterogeneity is one of the major unmet need and intense research field in immuno-oncology. This review will discuss the host metabolic dysfunctions derived from cachexia or obesity that can affect the response to cancer immunotherapy. Recent findingsPreclinical studies demonstrated that chronic inflammation, nutritional intake impairment and endocrine dysfunction may affect anticancer innate and adaptive immunity, both in cachexia and obesity. New emerging clinical findings have highlighted the impact of metabolic biomarkers in predicting response to immune checkpoint inhibitors in cancer patients. SummaryPatient's weight and inflammatory status could be relevant in the clinical decision-making process before starting cancer immunotherapy and for an effective patient selection and stratification in future clinical trials employing this class of anticancer agents.

show abstract

Cancer patients’ constitutional features as a predictor of the efficiency of immunotherapy

Дмитриев¹,

Lyadov²,

Lyadova³

et al. 2022

Onkol. Z. im. P.A. Gercena

View full text Add to dashboard Cite

Sarcopenia and inflammation predicts survival in advanced stage cancer patients (pts) treated with immunotherapy (IO)

Cited by 3 publications

References 0 publications

Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review

Immune checkpoint inhibitors in elderly patients treated for a lung cancer: a narrative review

From cachexia to obesity: the role of host metabolism in cancer immunotherapy

Cancer patients’ constitutional features as a predictor of the efficiency of immunotherapy

Contact Info

Product

Resources

About